Company Analysis
Sign in

RxSight, Inc. (RXST)

Nasdaq: RXST · Ophthalmic Goods · Aliso Viejo, CA · filing with the SEC since 2002
Full chart Alerts Compare
Grade5.1
◀ Past 5.4● Present 4.6▶ Future 5.6
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$134M-3.9%
Net income-$38.9M-41.8%
Earnings per share$-0.95-33.8%
Operating cash flow-$15.5M+8.5%
Cash$20.7M+18.6%
Debtn/a
Shareholders’ equity$276M-2.0%
Shares, diluted40.9M+5.1%
Return on equity-14.1%
The recordfrom its filings
Filings in 202671
Newest filingNov 10 · SCHEDULE 13G
Annual reportFeb 25, 2026
Quarterly reportNov 3, 2026
Next report due10-K by Mar 16
Insider sales, 12 months$100,000
Insider buys, 12 months$0.00
Patents granted38
Filer categoryAccelerated filer
Trailing twelve months to Sep 2026Revenue $115MNet income -$53.4MCash from operations $23.7Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 10, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
Nov 3, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Nov 3, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Sep 16, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 9, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 9, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton RXST · research, not advice